๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Drug discovery and development, Vol. 1: Drug discovery

โœ Scribed by Robert H. Glew


Publisher
The American Society for Biochemistry and Molecular Biology
Year
2007
Tongue
English
Weight
25 KB
Volume
35
Category
Article
ISSN
1470-8175

No coin nor oath required. For personal study only.

โœฆ Synopsis


Drug Discovery and Development, edited by M.S. Chorghade, is a two volume set, the first of which is now available. Volume 1, Drug Discovery, is composed of 16 chapters by authors who are active in the field of medicinal chemistry and are able to bring historical perspective to this important field of chemistry. Chapter 2 ''Medicinal Chemistry in the New Millenium: A Glance into the Future'' by Paul Erhardt is a long chapter that places the other chapters into context and gives the reader numerous examples of drug development that help to make the important teaching points of this book clear and meaningful. This is not a textbook, however, and is not designed to teach the synthetic organic chemistry and physical organic chemistry that underpin medicinal chemistry. Nevertheless, there are numerous sections on synthetic chemistry as applied to drug development, especially in some of the later chapters that are devoted to development of specific drugs.

Undergraduate students and graduate students can learn much from this well-written collection of articles, especially if the book is used as a reference source in a seminar course designed to introduce the field of medicinal chemistry. This would be especially the case in Departments of Chemistry that traditionally do not offer courses in medicinal chemistry. The ever-changing field of medicinal chemistry is impacted by many other disciplined and emerging technologies, such that graduating undergraduates from traditional chemistry programs may not appreciate the challenges of modern medicinal chemistry and where this field will likely change in the future. This volume can help students to bridge this gap in their understanding of chemistry.


๐Ÿ“œ SIMILAR VOLUMES


The discovery and development of antiinf
โœ Kay Brune; Burkhard Hinz ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 406 KB ๐Ÿ‘ 1 views

Inflammation was one of the earliest recognized and defined disease entities. Celsus characterized inflammation by the 4 cardinal signs, namely, pain (dolor), redness (rubor), warmth (calor), and swelling (tumor); Galenius (others say Virchow) added "loss of function" (functio laesa). These signs ar

Genetics, Genomics, and Drug Discovery
โœ Tim Harris ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 72 KB ๐Ÿ‘ 2 views

Genetics and genomics are altering the drug discovery process and changing the practice of medicine. Genetic mapping and positional cloning will lead to the identification of disease susceptibility alleles of different genes and this will be further enabled by the publication of the DNA sequence of

Structural chemoproteomics and drug disc
โœ Dongkyu Shin; Yong-Seok Heo; Kyung Joo Lee; Cheol Min Kim; Jung Min Yoon; Jae Il ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 307 KB

## Abstract Our laboratories have developed several technologies to accelerate drug discovery process on the basis of structural chemoproteomics. They include __SPS__โ„ข technology for the efficient determination of protein structures, __SCP__โ„ข technology for the rapid lead generation and __SDF__โ„ข te

Bioinformatics in drug discovery
โœ David T. Kingsbury ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB

It is estimated that when the Human Genome Project's DNA sequencing phase reaches it peak steady-state, the production rate will be approximately 70 to 80 "new" genes each day, every day. This estimate is based on genomic sequencing and not expressed sequence tags (ESTs) or full-length cDNA sequenci